We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
-9.77%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.23B
AUM Growth
-$307M
Cap. Flow
+$10.8M
Cap. Flow %
0.88%
Top 10 Hldgs %
46.8%
Holding
78
New
13
Increased
11
Reduced
35
Closed
8

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$23.1M
2
AXNX
Axonics, Inc. Common Stock
AXNX
+$19.1M
3
TWST icon
Twist Bioscience
TWST
+$15.6M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$14.1M
5
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
+$13.3M

Top Sells

Rank Stock Value
1
AUTL
Autolus Therapeutics
AUTL
+$40.7M
2
NKTR icon
Nektar Therapeutics
NKTR
+$33.1M
3
TSRO
TESARO, Inc.
TSRO
+$16.8M
4
OMER icon
Omeros
OMER
+$14M
5
SPPI
Spectrum Pharmaceuticals Inc
SPPI
+$8.4M

Sector Composition

Rank Sector Weight
1 Healthcare 86.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XFOR icon
51
X4 Pharmaceuticals
XFOR
$391M
$4.32M 0.35%
+10,343
New +$3.95M
HRTX icon
52
Heron Therapeutics
HRTX
$95.5M
$4.3M 0.35%
165,682
-4,318
-3% -$119K
COLL icon
53
Collegium Pharmaceutical
COLL
$1.16B
$4.21M 0.34%
245,370
-4,630
-2% -$79.2K
NERV icon
54
Minerva Neurosciences
NERV
$203M
$4.1M 0.33%
75,988
– –
YMAB
55
DELISTED
Y-mAbs Therapeutics
YMAB
$3.96M 0.32%
194,768
-5,232
-3% -$120K
ACRS icon
56
Aclaris Therapeutics
ACRS
$888M
$3.53M 0.29%
478,055
-21,945
-4% -$226K
ABEO icon
57
Abeona Therapeutics
ABEO
$388M
$3.49M 0.28%
19,541
-459
-2% -$100K
TBIO
58
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$3.41M 0.28%
454,550
– –
PHAS
59
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$3.39M 0.28%
+1,097,926
New +$4.35M
CRSP icon
60
CRISPR Therapeutics
CRSP
$5.17B
$2.86M 0.23%
+100,000
New +$3.48M
BOLD
61
DELISTED
Audentes Therapeutics, Inc
BOLD
$2.6M 0.21%
121,797
-3,203
-3% -$82.6K
ITRM
62
DELISTED
Iterum Therapeutics
ITRM
$2.33M 0.19%
31,067
-731
-2% -$69.2K
MGTX icon
63
MeiraGTx Holdings
MGTX
$1.16B
$2.3M 0.19%
238,579
– –
SGMO
64
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$2.23M 0.18%
194,274
-5,726
-3% -$71.1K
XLRN
65
DELISTED
Acceleron Pharma
XLRN
$2.12M 0.17%
48,695
-1,305
-3% -$65.2K
OMER icon
66
CALL
Omeros
OMER
$916M
$2.02M 0.16%
181,700
-955,200
-84% -$13.4M
QTRX icon
67
Quanterix
QTRX
$177M
$1.01M 0.08%
54,945
– –
ARQL
68
DELISTED
Arqule Inc
ARQL
$809K 0.07%
292,095
-7,905
-3% -$30.2K
OTLKW
69
DELISTED
Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
$64K 0.01%
+416,666
New +$52.5K
CLRBW
70
DELISTED
Cellectar Biosciences, Inc.
CLRBW
$3K ﹤0.01%
52,999
– –
AUTL
71
Autolus Therapeutics
AUTL
$506M
– –
-1,326,136
Closed -$40.7M
CLSD
72
DELISTED
Clearside Biomedical
CLSD
– –
-26,667
Closed -$2.46M
OMER icon
73
Omeros
OMER
$916M
– –
-1,000,000
Closed -$14M
MRNS
74
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-75,000
Closed -$3M
SPPI
75
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
– –
-500,000
Closed -$8.4M
1 2
3
4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q4 2018 Portfolio in Review

As of Q4 2018, Cormorant Asset Management held 78 positions worth $1.23B, down 20% from $1.54B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Cormorant Asset Management's Q4 2018 filing shows 13 new, 11 increased, 35 reduced and 8 closed positions. Its largest new stake was Axonics, Inc. Common Stock: 1,285,828 shares worth $19.4M. The largest sale was Autolus Therapeutics, an estimated $40.7M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 87% a quarter earlier.

  • Cormorant Asset Management's largest Q4 2018 buy was Axonics, Inc. Common Stock: 1,285,828 shares worth $19.4M.
  • Cormorant Asset Management added most to argenx in Q4 2018, an estimated $23.1M increase.
  • Cormorant Asset Management's biggest Q4 2018 reduction was Nektar Therapeutics, cutting an estimated $33.1M.
  • Cormorant Asset Management fully exited Autolus Therapeutics in Q4 2018, selling an estimated $40.7M.
  • Cormorant Asset Management's ten largest holdings make up 47% of its $1.23B portfolio in Q4 2018.
  • Cormorant Asset Management opened 13 new positions and closed 8 in Q4 2018.
  • Cormorant Asset Management's portfolio value fell 20% quarter-over-quarter to $1.23B.

Based on Cormorant Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.